drugset / Trial / NCT06144697
A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants
RandomizedSequentialQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese ethnicity.
Timeline
- Start
- 2024-01-29
- Primary completion
- 2024-10-16
- Completion
- 2024-10-16
Outcome
Outcome not reported
Stopped (Business): “Business objectives have changed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986465 | Unknown | — | — |
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |
| Background | Famotidine | Other / unclassified | — | — |
Indications
No indication recorded.